
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
The Antibacterial Resistance Leadership Group (ARLG), a unique research network for which the Duke Clinical Research Institute (DCRI) acts as a coordinating center, received a federal award worth up to $102.5 million over seven years that will continue the ARLG. The Antibacterial Resistance Leadership Group conducts clinical research to better understand how to diagnose, treat, and prevent antibacterial resistant infections.
To learn more, click






